Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06337708
Other study ID # STUDY00017286
Secondary ID R01HL168170
Status Recruiting
Phase Phase 2
First received
Last updated
Start date January 19, 2024
Est. completion date March 31, 2028

Study information

Verified date March 2024
Source Arizona State University
Contact Rodney P Joseph, PhD
Phone 602-496-0772
Email rodney.joseph@asu.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to test a culturally tailored, smartphone-delivered intervention designed to increase physical activity and reduce risk for heart disease and type 2 diabetes among African American women.


Description:

This study addresses major public health concerns among African American women: physical inactivity and cardiometabolic disease risk. African American women experience a high burden of cardiometabolic diseases, including heart disease, obesity, and type 2 diabetes. Regular aerobic physical activity is an established behavior to prevent and treat these conditions. Yet, the many African American women are insufficiently active, with only 27-40% meeting national aerobic physical activity guidelines. This study will test the efficacy of Smart Walk, a culturally tailored, theory-based smartphone-delivered intervention designed to increase physical activity and improve cardiometabolic disease risk factors among African American women. In a 12-month trial, participants will be randomly assigned to either the Smart Walk intervention or a Fitbit-only comparison arm for an active 4-month intervention period, followed by an 8-month minimal contact follow-up period. Specific Aims: 1. Test the effects of Smart Walk to increase physical activity and promote adherence to national aerobic physical activity guidelines; compared to Fitbit-only comparison group. 2. Test the effects of Smart Walk to improve cardiometabolic risk factors; compared to Fitbit-only comparison group. 3. Compare cost and cost effectiveness of the two intervention groups from a societal perspective. 4. Examine if protocol adherence predicts outcomes and potential mediation and moderation of intervention effects on physical activity and cardiometabolic outcomes.


Recruitment information / eligibility

Status Recruiting
Enrollment 240
Est. completion date March 31, 2028
Est. primary completion date March 31, 2027
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 24 Years to 65 Years
Eligibility Inclusion Criteria: - Self-reported African American/Black female - Aged of 24-65 years - Insufficiently Active (< 60 minutes of moderate-to-vigorous physical activity per week as measured by Exercise Vital Sign Questionnaire) - BMI > 30 kg/m2 - English speaking and reading - Ownership of a smartphone with the ability to download applications (i.e., apps) - Ownership of a smartphone with the ability to receive text messages - Willingness to receive a physical activity intervention delivered through their smartphone - Willingness to include their first name or create an alias to be used on their profile page on the Smart Walk app Exclusion Criteria: - Plans to relocate out of Phoenix area in next 12 months - Endorsing an item on the Physical Activity Readiness Questionnaire (PAR-Q), unless a doctor's note for study participation in provided - Resting systolic blood pressure greater than 180 mmHG and/or a diastolic blood pressure greater than 120 mmHG , as assessed at baseline or at any other study assessment - Self-reported participation in another diet or weight loss study at screening - Pregnant or planning to become pregnant in the next 12 months

Study Design


Intervention

Behavioral:
Smart Walk
Smart Walk is a culturally tailored, Social Cognitive Theory-based multi-component smartphone delivered physical activity (PA) promotion intervention that delivered through the Smart Walk application, virtual physical activity coaching, and text messages. The Smart Walk smartphone application includes four key features: 1) personal profile pages, 2) culturally relevant multi-media physical activity promotion modules, 3) discussion boards, and 4) physical activity self-monitoring/tracking feature that integrates with Fitbit activity monitors for participants to track their daily, weekly, and monthly activity. Virtual physical activity coaches will actively engage and facilitate group-based dialogue among participants on the app discussion boards and provide individualized, one-on-one PA coaching via telephone or commercially available app-based video teleconferencing software (i.e., FaceTime, Zoom, Google hangouts).
Fitbit
This intervention group will receive a Fitbit activity monitor and be encouraged to use the commercially available device to increase physical activity.

Locations

Country Name City State
United States Arizona State University Phoenix Arizona

Sponsors (2)

Lead Sponsor Collaborator
Arizona State University National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Treatment acceptance Survey assessing acceptance, feasibility, and consumer satisfaction of intervention. Assessed at 4-months and 12-months
Other Protocol Adherence Fitbit wear, app utilization, and adherence to physical activity coaching session protocols will be assessed as moderators. Assessed at 4-months and 12-months
Other Program costs Costs borne by the program, including Fitbit activity monitors, Smart Walk app development, and all personnel salaries/hourly wages. Assessed at 4-months and 12-months
Other Participant costs Participant costs associated with study participation, including time spent using the Smart Walk app, time spent in physical activity coaching, and cellular phone data charges over their plan limit. Assessed at 4-months and 12-months
Other Cost-effectiveness Cost effectiveness will be evaluated by combining the mean total cost per participant with effectiveness (baseline to 12-month changes in minutes/week of moderate-to-vigorous physical activity). We will calculate the incremental cost effectiveness ratios (ICER) for the Smart Walk intervention compared to the Fitbit comparison arm. Assessed at 4-months and 12-month
Other Objectively-measured home neighborhood characteristics GIS mapping and computer vision techniques will be used to assess macro-scale and micro-scale home neighborhood environment characteristics of participants. Assessed at baseline
Other Subjectively-measured Neighborhood environment walkability Subjectively-measured Neighborhood Environment Walkability will be measured using the Neighborhood Environment Walkability Scale (NEWS). This measure includes 43 items and assesses the following environmental characteristics: residential density (6-items, possible range of scores range 1-5), land use mix-diversity (22 items, possible range of scores range 1-5), street connectivity (2 items, possible range of scores range 1-4), walking/cycling facilities (6 items, possible range of scores range 1-4), aesthetics (4 items, possible range of scores 1-4), pedestrian/traffic safety (3 items, possible range of scores 1-4). Higher scores indicate greater walkability. Assessed at baseline
Other Race-related Stress Race-related stress, as a result of experiencing individual, cultural and institutional racism, will be assessed using the 22-item Index of Race-Related Stress-Brief survey. This survey has a possible score range of 0 to 88, with higher scored indicating greater stress as a result of experiencing racism. Assessed at baseline
Other Perceived Structural Racism Structural racism will be assessed using the 20-item Perceived Structural Racism Scale. This scale has a possible scoring range of 20-120 with higher scores indicating greater levels of perceived structural racism. Assessed at baseline
Primary Change in accelerometer-measured moderate-to-vigorous intensity physical activity from baseline to 4- and 12-months Participants will wear wrist-worn ActiGraph GT9X Link Activity monitors the activity monitor on their non-dominant wrist during all waking hours for 7 consecutive days to provide an assessment of usual activity Assessed at baseline, 4-months, 12-months
Primary Change in self-reported moderate-to-vigorous intensity physical activity from baseline to 4- and 12-months Assessed by the 7-Day Physical Activity Recall Assessed at baseline, 4-months, 12-months
Secondary Change in cardiorespiratory fitness from baseline to 4- and 12-months A modified Balke treadmill protocol will be used to estimate maximal aerobic capacity (i.e., VO2 peak). Assessed at baseline, 4-months, 12-months
Secondary Change in aortic pulse wave velocity from baseline to 4- and 12-months A measure of aortic stiffness and will be assessed using SphygmoCor XCEL system using validated methodology. Assessed at baseline, 4-months, 12-months
Secondary Change in body weight from baseline to 4- and 12-months. Measured in kilograms using an electronic scale Assessed at baseline, 4-months, 12-months
Secondary Change in body mass index from baseline to 4- and 12-months Calculated using the formula: weight (in kilograms) / height (in meters)squared Assessed at baseline, 4-months, 12-months
Secondary Change in waste circumference from baseline to 4- and 12-months Measured in centimeters Assessed at baseline, 4-months, 12-months
Secondary Change in blood pressure (mmHG) from baseline to 4- and 12-months Both systolic and diastolic blood pressure will be assessed using electronic sphygmomanometer following 5-min rest Assessed at baseline, 4-months, 12-months
Secondary Change in tumor necrosis factor-alpha (TNF-a) from baseline to 4- and 12-months Measured in serum using a commercial multiplex immunoassay platform; blood will be drawn after a 10 hour fast. Assessed at baseline, 4-months, 12-months
Secondary Change in interleukin 6 (IL-6) from baseline to 4- and 12-months Measured in serum using a commercial multiplex immunoassay platform; blood will be drawn after a 10 hour fast. Assessed at baseline, 4-months, 12-months
Secondary Change in interleukin 10 (IL-10) from baseline to 4- and 12-months Measured in serum using a commercial multiplex immunoassay platform; blood will be drawn after a 10 hour fast. Assessed at baseline, 4-months, 12-months
Secondary Change in interleukin 15 (IL-15) from baseline to 4- and 12-months Measured in serum using a commercial multiplex immunoassay platform; blood will be drawn after a 10 hour fast. Assessed at baseline, 4-months, 12-months
Secondary Change in fasting blood glucose glucose from baseline to 4- and 12-months Plasma glucose assessed after a 10 hour fasting blood draw. Measured using an automated chemistry analyzer. Assessed at baseline, 4-months, 12-months
Secondary Change in serum insulin from baseline to 4- and 12-months Serum insulin collected after a 10 hour fasting blood draw. Assessed at baseline, 4-months, 12-months
Secondary Change in serum lipids (mg/DL) from baseline to 4- and 12-months Triglycerides, total cholesterol, LDL-C, and HDL-C will be assessed Assessed at baseline, 4-months, 12-months
Secondary Change in insulin sensitivity (µIU/mL) from baseline to 4- and 12-months Assessed by calculating homeostatic model assessment (HOMA) scores as: glucose (mg/dl) x insulin (µU/ml)/405. Assessed at baseline, 4-months, 12-months
Secondary Change in exercise self-efficacy from baseline to 4- and 12-months Assessed by the 12-item Exercise Self-Efficacy survey (Sallis et al.1987). The range of possible scores for this measure is 1-5, with higher scores indicating higher levels of physical activity self-efficacy. Assessed at baseline, 4-months, 12-months
Secondary Change in self-regulation for physical activity from baseline to 4- and 12-months Assessed by the 10- item Self-Regulation Scale from the Health Beliefs Survey (Anderson-Bill 2006). This scale assesses the use of behavioral strategies to incorporate physical activity into daily activities (i.e., take stairs instead of elevator, walking instead of driving when running errands). The range of possible scores for this measure is 1-5, with higher scores indicating higher levels of physical activity self-regulation. Assessed at baseline, 4-months, 12-months
Secondary Change in social support for physical activity from baseline to 4- and 12-months Assessed by the Social Support for Exercise survey developed by Sallis et al (1987). This scale assesses social support from family support (10-items, with a possible range of scores from 10-50) and friends (8-items, with a possible score range from from 8-40). Higher scores indicate greater levels of social support. Assessed at baseline, 4-months, 12-months
Secondary Change in outcome expectations for physical activity from baseline to 4- and 12-months Assessed using the 9-item Outcome Expectation Scale for Exercise scale, developed by Resnick (2000). The range of possible scores for this measure is 1-5, with higher scores indicating more positive expectancies associated with physical activity engagement. Assessed at baseline, 4-months, 12-months
Secondary Change in behavioral capability for physical activity from baseline to 4- and 12-months Assessed using a 6-item scale developed by the research team in previous research. The range of possible scores for this measure is 1-6, with higher scores indicating higher levels of behavioral capability of physical activity. Assessed at baseline, 4-months, 12-months
See also
  Status Clinical Trial Phase
Completed NCT03743779 - Mastering Diabetes Pilot Study
Completed NCT03786978 - Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus N/A
Completed NCT01804803 - DIgital Assisted MONitoring for DiabeteS - I N/A
Completed NCT05039970 - A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04068272 - Safety of Bosentan in Type II Diabetic Patients Phase 1
Completed NCT03243383 - Readmission Prevention Pilot Trial in Diabetes Patients N/A
Completed NCT03730480 - User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS) N/A
Recruiting NCT02690467 - Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm. N/A
Completed NCT02229383 - Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus Phase 3
Completed NCT06181721 - Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT04489043 - Exercise, Prediabetes and Diabetes After Renal Transplantation. N/A
Withdrawn NCT03319784 - Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients Phase 4
Completed NCT03542084 - Endocrinology Auto-Triggered e-Consults N/A
Completed NCT02229396 - Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Phase 3
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Completed NCT01892319 - An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Completed NCT05031000 - Blood Glucose Monitoring Systems: Discounter Versus Brand N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A